17 May 2021

17th Amendment to the Foreign Trade and Payments Ordinance now in force

Fourth Amendment for tightening Investment Screening within one year.

On 1 May 2021, the 17th Amendment to the Foreign Trade and Payments Ordinance entered into force. This is already the fourth change to Germany’s investment screening under foreign trade law within one year, creating additional hurdles for non-EU parties when it comes to investing in German companies. This amendment includes an expansion to the reporting obligation for investments representing a stake of at least 20%, now covering additional industry sectors in next generation technologies, such as artificial intelligence, autonomous driving, semiconductors, optoelectronics, and quantum technology.

Our GSK Update summarizes the key changes under this amendment and illuminates what investors who are domiciled outside of the EU will need to keep in mind in the future when investing in German businesses.

Print


Press contact
Christine Ström
+49 30 203907-7763
presse@gsk.de

Back

GSK Updates
  • 24 August 2021

    GSK Update: New marketing rules for investment management companies

    Read more
  • 23 June 2021

    GSK Update: The new German law on corporate due diligence in supply chains

    Read more
  • 21 June 2021

    GSK Update: Global data transfer: The new standard data protection clauses – What needs to be done?

    Read more
Contact person

Dr. Andreas Bauer, LL.M.

Partner*

+49 89 288174-74

andreas.bauer@gsk.de

* Partner: A partner within the meaning of the partnership company law.
   Local Partner: not a partner within the meaning of the partnership company law.
CO2 Neutral